|
KMID : 0387820090160010059
|
|
Clinical Pediatric Hematology-Oncology
2009 Volume.16 No. 1 p.59 ~ p.64
|
|
|
Gemtuzumab Ozogamicin (Mylotargⓡ) as a Single Consolidation Therapy in Relapsed Pediatric Acute Myeloid Leukemia Patient: a Patient Who Refused Transfusion and Stem Cell Transplantation for Religious Belief
|
|
Lee Ha-Neul
Kim Hyo-Sun
Kwon Seung-Yeon
Won Sung-Chul
Kim Bum-Sik
Choi Seong-Yeol
Yang Woo-Ick
Lyu Chuhl-Joo
|
|
|
Abstract
|
|
|
|
Despite improvement of long-term survival rate in pediatric acute myeloid leukemia (AML) during the last two decades, relapse/refractory disease remains a major obstacle to further improvement of prognosis. Moreover, there are only few therapeutic options which stimulate investigations for targeted, less toxic therapy. Gemtuzumab ozogamicin (GO, Mylotargⓡ) is an anti-CD33 monoclonal antibody and there are ongoing studies evaluating safety and efficacy of this drug in relapsed/refractory AML patients. Still, the response rate is only 30% and the response does not last more than a year. We present a case of pediatric central nervous system relapsed AML who was treated with GO as a single consolidation therapy without stem cell transplantation because of religious belief and maintained CR status for more than 3 years.
|
|
|
KEYWORD
|
|
|
Pediatric, Acute myeloid leukemia, Gemtuzumab ozogamicin, Mylotarg
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|